Canopy Growth Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
55.2%projected annual EPS growth
Analyst Coverage
1analyst covering
FY Revenue (est.)
$243.2Mnext fiscal year
FY EPS (est.)
-$0.05next fiscal year
Monitoring Framework
Key Performance Indicators
Consolidated Net Revenue (CAD) Quarterly284.6MTarget: Sequential growth in FY2027
Canada Medical Cannabis Net Revenue (CAD) Quarterly25.3MTarget: Maintain market leadership post-MTL Cannabis acquisition
Adjusted EBITDA (CAD) Quarterly-20.2MTarget: Positive Adjusted EBITDA in FY2027
Free Cash Flow Outflow (CAD) Quarterly-69.1MTarget: Continued reduction in cash burn
Watch Items
- Integration of MTL Cannabis Corp.Trigger: Consolidation of premium indoor flower supply and realization of cost synergiesAction: Monitor gross margin improvements in the Canadian cannabis segment
- U.S. THC Market Entry via Canopy USA, LLCTrigger: Federal regulatory shifts (e.g., potential Schedule III rescheduling or 280E tax relief)Action: Track financial performance of unconsolidated non-controlling interests
- Remediation of Material Weakness in Internal ControlsTrigger: Ineffective internal control over financial reporting as of March 31, 2026Action: Review progress of remediation plans in subsequent quarterly 10-Q filings
Research as of 19 Jun 2026